Medical Condition News

RSS

Survey: 25% of employers have little or no understanding of specialty pharmacy, costs

Twenty-five percent of employers have little or no understanding of specialty pharmacy and 53 percent have only a moderate understanding of this challenging benefit according to a new survey released by the non-profit Midwest Business Group on Health (MBGH), one of the nation's leading business groups of private and public employers.

30 Sep 2011

Six sneaky triggers of allergies and asthma

Halloween can be a frightful time for parents of kids with allergies and asthma. Nut-filled candy isn't the only bogeyman that can ruin the fun. Allergy and asthma triggers can hide in other, unexpected places, too, from dusty costumes to leering jack-o-lanterns.

30 Sep 2011

Researchers identify set of proteins that affect development of varicose veins

A new discovery published in the October 2011 print issue of The FASEB Journal explains for the first time what kicks off the process that causes varicose veins.

30 Sep 2011

GSA, NAM select 16 reporters for MetLife Foundation Journalists in Aging Fellows Program

The Gerontological Society of America (GSA) and New America Media (NAM) have selected 16 reporters for the MetLife Foundation Journalists in Aging Fellows Program, now in its second year.

30 Sep 2011

PTK6 protein may play a different role in colon and breast cancer

A protein that regulates cell differentiation in normal tissue may play a different role in colon and breast cancer, activating proliferation of damaged cells, according to researchers at the University of Illinois at Chicago College of Medicine.

30 Sep 2011

Many Canadians are not screening for glaucoma earlier, finds study

Glaucoma is the second leading cause of blindness worldwide. Although it can be treated, new research shows Canadians may not be doing enough to protect themselves. According to a new study by Lawson Health Research Institute's Dr. Cindy Hutnik, many Canadian glaucoma patients are not screened until the disease has reached moderate or advanced stages.

30 Sep 2011

Resveratrol inhibits proliferation of hormone resistant breast cancer cells

Cheers! A new research report appearing in the October 2011 issue of The FASEB Journal shows that resveratrol, the "healthy" ingredient in red wine, stops breast cancer cells from growing by blocking the growth effects of estrogen.

30 Sep 2011

Immune cells in brain linked with behavioural responses to alcohol

University of Adelaide researchers have found that immune cells in your brain may contribute to how you respond to alcohol.

30 Sep 2011

VDC and P.A.D. Coalition present annual research awards at VDF's eighth annual meeting

The Venous Disease Coalition (VDC) and Peripheral Arterial Disease Coalition presented their annual research awards at the Vascular Disease Foundation's eighth annual meeting in Washington.

30 Sep 2011

FDA approves NeuRx Diaphragm Pacing System to treat ALS

An electronic system that stimulates the nerve of the diaphragm muscles has received approval from the Food and Drug Administration (FDA) for use in patients with Amyotrophic Lateral Sclerosis (ALS), also known as Lou Gehrig's disease.

30 Sep 2011

Cedars-Sinai to co-sponsor World Stem Cell Summit

Six leaders in stem cell research from the Cedars-Sinai Regenerative Medicine Institute will be key presenters at the world's largest interdisciplinary stem cell meeting Oct. 3-5 in Pasadena, Calif.

30 Sep 2011

MRI-based technique allows researchers to follow neural stem cells in vivo

Carnegie Mellon University biologists have developed an MRI-based technique that allows researchers to non-invasively follow neural stem cells in vivo.

30 Sep 2011

Cocaine use linked to increased risk of open-angle glaucoma

A study of the 5.3 million men and women seen in Department of Veterans Affairs outpatient clinics in a one-year period found that use of cocaine is predictive of open-angle glaucoma, the most common type of glaucoma.

30 Sep 2011

G-Zero receives NIAID's Phase II Small Business Innovation Research Grant

G-Zero Therapeutics, an RTP company started in 2008 based on technologies from the University of North Carolina at Chapel Hill, has been awarded a $3 million Phase II Small Business Innovation Research Grant from the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health.

30 Sep 2011

Study provides insight into earliest stages of some cancers

A novel technique that enables scientists to measure and document tumor-inducing changes in DNA is providing new insight into the earliest events involved in the formation of leukemias, lymphomas and sarcomas, and could potentially lead to the discovery of ways to stop those events.

30 Sep 2011

Oral steroid users twice as likely to have severe vitamin D deficiency

People taking oral steroids are twice as likely as the general population to have severe vitamin D deficiency, according to a study of more than 31,000 children and adults by scientists at Albert Einstein College of Medicine of Yeshiva University.

30 Sep 2011

Invida, Sinclair IS launch two dermatology products in seven Asia-Pacific markets

Sinclair IS Pharma Plc, the international specialty pharmaceutical company, and Invida Holdings Private Limited, a leader in the commercialisation of specialty biopharmaceutical and healthcare products throughout Asia Pacific, announce that their partnership has already led to the launch of two Sinclair IS dermatology products in seven Asia-Pacific markets.

30 Sep 2011

Beta-blockers can prevent breast cancer metastasis and improve survival

Cancer Research UK scientists are investigating whether beta-blockers hold the key to preventing breast cancer spread and improving survival. Promising early results will be presented on the eve of breast cancer awareness month at the Royal Society of Medicine.

30 Sep 2011

Enrollment begins in Boston Scientific's vagal nerve stimulation trial for heart failure

Boston Scientific Corporation has enrolled the first patients in its NECTAR-HF (NEural Cardiac TherApy foR Heart Failure) clinical trial. NECTAR-HF is a prospective, randomized, international clinical feasibility study designed to assess preliminary safety and efficacy of chronic vagal nerve stimulation in heart failure patients.

30 Sep 2011

Cardiac Dimensions' enhanced version of CARILLON system receives CE Mark approval

Cardiac Dimensions, Inc. today announced that it has received Conformite Europeenne (CE) Mark approval for a newly enhanced version of its CARILLON Mitral Contour System, a novel therapy for treating heart failure patients suffering from functional mitral regurgitation.

30 Sep 2011